Venture Certified
| 벤처투자유형 | 2022-06-15 ~ 2025-06-14 | 20220615010030 | 2022-06-15 |
| 벤처투자유형 | 2025-06-15 ~ 2028-06-14 | 20250611010023 | 2022-06-15 |
Revenue CAGR -1.1%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.4B | 0.0B | 0.4B |
| Operating Profit | -1.2B | -0.1B | -0.1B |
| Net Profit | -1.0B | -0.0B | -0.1B |
| Total Assets | 9.3B | 6.5B | 4.1B |
| Total Liabilities | 4.2B | 0.4B | 0.2B |
| Total Equity | 5.1B | 6.1B | 3.9B |
Operating Loss: Op. profit -1B
3 Consecutive Years of Net Loss
Debt Ratio Surge (+78pp YoY)
▲ 73.8%
▼ 1065.9%
▼ 236.1%
▲ 1291.3%
▼ 820.9%
| Name | Position | Role |
|---|---|---|
| 김재윤 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "경상북도 포항시",
"ceo_name": "김재윤",
"certificate": [
{
"cert_number": "20220615010030",
"changes": "",
"disclosure_date": "2022-06-15",
"first_cert_date": "2022-06-15",
"no": "1",
"type": "벤처투자유형",
"valid_period": "2022-06-15 ~ 2025-06-14"
},
{
"cert_number": "20250611010023",
"changes": "",
"disclosure_date": "2025-06-11",
"first_cert_date": "2022-06-15",
"no": "2",
"type": "벤처투자유형",
"valid_period": "2025-06-15 ~ 2028-06-14"
}
],
"company_name": "주식회사 바이오엔",
"corp_no": "171711-*******",
"financials": {
"2022": {
"capital_stock": 111111000,
"cost_of_sales": 0,
"current_assets": 214297000,
"current_liabilities": 23455000,
"gross_profit": 36364000,
"net_income": -14554000,
"net_income_bs": -14554000,
"non_current_assets": 194601000,
"non_current_liabilities": 0,
"non_operating_expenses": 1768000,
"non_operating_income": 217000,
"operating_profit": -13003000,
"revenue": 36364000,
"sga_expenses": 49367000,
"total_assets": 408898000,
"total_equity": 385443000,
"total_liabilities": 23455000
},
"2023": {
"capital_stock": 117101000,
"cost_of_sales": 0,
"current_assets": 333502000,
"current_liabilities": 36457000,
"gross_profit": 4545000,
"net_income": -4253000,
"net_income_bs": -4253000,
"non_current_assets": 314142000,
"non_current_liabilities": 0,
"non_operating_expenses": 24000,
"non_operating_income": 3213000,
"operating_profit": -7442000,
"revenue": 4545000,
"sga_expenses": 11987000,
"total_assets": 647644000,
"total_equity": 611187000,
"total_liabilities": 36457000
},
"2024": {
"capital_stock": 117101000,
"cost_of_sales": 0,
"current_assets": 618040000,
"current_liabilities": 424861000,
"gross_profit": 35545000,
"net_income": -104355000,
"net_income_bs": -104355000,
"non_current_assets": 313653000,
"non_current_liabilities": 0,
"non_operating_expenses": 846000,
"non_operating_income": 15674000,
"operating_profit": -119183000,
"revenue": 35545000,
"sga_expenses": 154728000,
"total_assets": 931693000,
"total_equity": 506832000,
"total_liabilities": 424861000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "300,000,000",
"changes": "300,000,000",
"date": "2022-04-21"
},
{
"amount": "299,997,000",
"changes": "299,997,000",
"date": "2022-04-21"
}
],
"main_products": "신약개발",
"phone": "010-3254-****",
"years": [
2024,
2023,
2022
]
}